Showing results (801-810 of 832) with videos related to
Sort By:
Pageof 84
Journal of Virology|July 2, 2024
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunitySimone I Richardson, Nonkululeko Mzindle, Thopisang Motlou, et al.Ebiomedicine|November 27, 2019
OLA-Simple: A software-guided HIV-1 drug resistance test for low-resource laboratoriesNuttada Panpradist, Ingrid A Beck, Justin Vrana, et al.Annals of Internal Medicine|September 10, 2019
Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized TrialJoAnn E Manson, Aaron K Aragaki, Shari S Bassuk, et al.Journal of the American College of Cardiology|July 14, 2022
Contributions of the Women's Health Initiative to Cardiovascular Research: JACC State-of-the-Art ReviewMichael J LaMonte, JoAnn E Manson, Garnet L Anderson, et al.Biorxiv : the Preprint Server for Biology|March 10, 2021
SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesThandeka Moyo-Gwete, Mashudu Madzivhandila, Zanele Makhado, et al.Cell Host & Microbe|April 18, 2022
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individualsSimone I Richardson, Vimbai Sharon Madzorera, Holly Spencer, et al.Cell Reports. Medicine|April 27, 2022
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concernDale Kitchin, Simone I Richardson, Mieke A van der Mescht, et al.Cell Reports. Medicine|January 5, 2023
Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variantSimone I Richardson, Prudence Kgagudi, Nelia P Manamela, et al.Nature|April 2, 2025
Bifidobacteria support optimal infant vaccine responsesFeargal J Ryan, Michelle Clarke, Miriam A Lynn, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2025
HIV resistance to dolutegravir varies with co-administered agentsIngrid A Beck, Ceejay L Boyce, Marley D Bishop, et al.Pageof 84